Key2Brain

Executive Summary

Key2Brain is a Swedish biotechnology company founded in 2018, headquartered in Stockholm, that is developing a modular blood-brain barrier (BBB) shuttle platform based on engineered single-domain antibodies (VHHs) targeting the transferrin receptor (TfR). This platform is designed to enable the delivery of a wide range of therapeutics to the central nervous system (CNS), addressing a major hurdle in treating neurological diseases. The company's business model combines internal development of pipeline candidates with strategic partnerships to license its technology for CNS applications. Key2Brain is currently in the pre-clinical stage, focusing on validating its platform through in vivo studies and advancing lead candidates toward IND-enabling studies. The company's technology has the potential to revolutionize CNS drug delivery by overcoming the restrictive nature of the BBB, which limits the effectiveness of many biologics and small molecules. With the increasing incidence of neurological disorders and the growing demand for effective treatments, Key2Brain's platform could unlock new therapeutic opportunities for conditions such as Alzheimer's disease, Parkinson's disease, and brain tumors. The company's strategic emphasis on partnerships with larger pharmaceutical companies provides a capital-efficient path to clinical development and commercialization. As it progresses toward the clinic, Key2Brain represents a compelling investment opportunity in the CNS drug delivery space.

Upcoming Catalysts (preview)

• Q3 2026Preclinical Proof-of-Concept Data for Lead BBB Shuttle Candidate60% success
• Q4 2026Strategic Partnership or Licensing Deal with Major Pharma40% success
• Q2 2026Series B Financing Round to Support IND-Enabling Studies70% success